

A) NAME, DATE AND PLACE OF BIRTH:

Francesco d'Amore, 4th September 1955, Genoa, Italy

B) POSITION AND TITLE:

Consultant Hematologist, M.D., DrMedScClinical Professor, M.D., DrMedSc

Dept. of Hematology, Clinical Research Institute

Aarhus University HospitalAarhus University

DK-8000 Aarhus CDK-8000 Aarhus C

DenmarkDenmark

C) EDUCATION:

1980 M.D. University of Genoa, Genoa, Italy

1981 Authorisation to practice Medicine in Italy

1981 Educational Commission for Foreign Medical Graduates (ECFMG) Examination (USA)

1981 Professional and Linguistic Assessment Board (PLAB) Examination, the General Medical Council (UK)

1981 Authorisation to practice Medicine in the UK

1982 Authorisation to practice Medicine in Denmark

1985 Specialist degree in Internal Medicine in Italy

1985 Specialist degree in Internal Medicine in Denmark

1997 Specialist degree in Haematology in Denmark

D) ACADEMIC DISSERTATIONS AND DEGREES:

1985 Specialty thesis, Faculty of Medicine, Genoa University, Genoa, Italy: "Phenotypical and functional characterisation of the malignant cell population in Hodgkin's disease"

2000 Dr. Sc. Med. thesis, Faculty of Medical Sciences, Aarhus University, Aarhus, Denmark: "Prediction of high risk disease in non-Hodgkin's lymphoma: Identification of clinicopathologic and molecular pretreatment prognostic factors in specific patient subsets"

E) CLINICAL APPOINTMENTS

1980-1982 Resident, Genoa University Hospital, Genoa, Italy

1984-1987 Senior House Officer, Dept. of Internal Medicine, Vejle Hospital, Vejle, Denmark

1987-1990 Senior Registrar, Dept. of Hematology, Odense University Hospital, Odense, Denmark

1996-1997 Senior Registrar, Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark

1997-1999 Senior Registrar/Consultant, Dept. of Oncology, Aarhus University Hospital, Aarhus, Denmark

1999- ...Chief Physician, Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark

F) ACADEMIC APPOINTMENTS

1982-1984 Postgraduate Research Scholarship (forskningsstipendium) from the Danish Ministry of Education at the University of Copenhagen, Lab. of Cancer Biology, Dept. of Hematology, Rigshospitalet

1990-1994 Research Fellow (klinisk assistent) at the University of Odense, Depts. of Hematology and Pathology

1994-1995 Postdoctoral Research Associate, Dept. of Pathology, University of Nebraska Medical Center, Omaha, Nebraska (Grant from the Danish Cancer Society and the Danish Medical Research Council)

1999-2010 Associate Professor, Faculty of Medical Sciences, Aarhus University, Aarhus, Denmark

2005 Visiting Professor, Dept. of Pathology, University of Nebraska Medical Center, Omaha, Nebraska (project: 'Clonal genetic progression in t(14;18)-positive follicular lymphomas'), June-September 2005

2010-... Clinical Professor, Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark

2011-2012 Guest Researcher, Metabolism Branch, Lymphoma Section, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA

G) TEACHING ACTIVITIES

1999- 2006: Responsible coordinator (kursusleder) of the clinical course for 8th and 9th semester medical students at Aarhus University Hospital (Aarhus Sygehus – Tage Hansens Gade)

1999- ...Theoretical and bedside teaching of 8th and 9th semester medical students; theoretical teaching of 12th semester medical students

1999-...Teaching at: PhD courses, A-courses for medical specialist training (e.g. haematology, oncology, nephrology, pediatrics, nuclear medicine), international educational symposia, educational nurse courses etc.

2001-... Member of the Examination Commission for Internal Medicine, Aarhus University, Faculty of Medicine

2010 April: A-kursus I nefrologi, Post-transplantation lymfoproliferative sygdomme. Rigshospitalet, København.

2010 June: Educational Session on peripheral T-cell lymphomas – European Hematology Association, Barcelona, Spain

2010 Nov: School of Molecular Medicine, Malignant lymphomas, Aarhus University, Aarhus, Denmark

2010 Dec.: Research course in pediatric hematology. Aarhus. Topic "Malignant lymphoma in children and adults: differences in biology, clinical features and management?"

2011 May: E-grandrounds – distance learning programme – on treatment of nodal T-cell lymphomas - European School of Oncology

2011 May: Post-graduate teaching course 'Lymphoma and CLL', as part of the specialization in Hematology for junior doctors- Topic 'Peripheral T-cell lymphomas, Copenhagen, Denmark

2012 Okt.: Inflammationskursus

2012 Nov. School of Molecular Medicine, Malignant Lymphomas, Aarhus University, Aarhus, Denmark

2013: Jan. Investigator initiated trials and Good Clinical Practice, Chairman and speaker, Bispebjerg Hospital

2014: Apr. Investigator initiated trials and Good Clinical Practice, Chairman and speaker, Bispebjerg Hospital.

H) SUPERVISOR ACTIVITY (ONGOING OR RECENTLY COMPLETED PHD STUDIES AND OTHER PROJECTS):

A) Main supervisor

1) Title: The biological and clinical significance of non-neoplastic bystander cells in Hodgkin lymphoma

Affiliation: Aarhus University, Depts. of Hematology, Pathology, Oncology and Medical Biochemistry

Phd student: Peter Kamper, cand.med.

Period: 2007-2010

Status: ACCOMPLISHED (Thesis Februar 4th 2010)

2)Title:Identifikation af prædiktive faktorer af betydningen for overlevelsen efter autolog stamcelletransplantation givet som recidivbehandling for Hodgkin Lymfom

Affiliation: Aarhus University Hospital, Dept. of Hematology

9.sem.stud.med.: Signe Albertsen & Louise Secher Jespersen

Period: 2009

Status: ACCOMPLISHED

3)Title:Identifikation af prædiktive faktorer af betydningen for overlevelsen efter autolog stamcelletransplantation givet som recidivbehandling for Hodgkin Lymfom

Affiliation: Aarhus University Hospital, Dept. of Hematology

9.sem.stud.med.: Annette Faber Svane & Kathrine Thiemer Christensen

Period: 2010

Status: ACCOMPLISHED

4)Title:Transformation af follikulære lymfomer. En populations-baseret opgørelse af forekomst, klinisk-patologiske egenskaber og prædiktive faktorer.

Affiliation: Aarhus University Hospital, Dept. of Hematology

9.sem.stud.med: Charlotte Madsen

Period: 2010

Status: ACCOMPLISHED

5)Title:Multiple myeloma and angiogenesis – impact of growth factors and gene polymorphisms for survival and effect of treatment with antingenesis inhibitors.

Affiliation: Aarhus University Hospital, Dept. of Hematology

Phd student: Niels Frost, cand. Med.

Period: 2010-2013

Status:ONGOING

6)Title:Peripheral T-cell lymphomas – a study to identify clinical, pathological and biological parameters to improve classification, prognostic assessment and treatment strategy

Affiliation: Aarhus University Hospital, Dept. of Hematology

Phd. Student: Martin Bjerregård Pedersen

Period: 2011 – 2014

Status:ONGOING

7)Title:Tumor Microenvironment in immunodeficiency-associated lymphoproliferative malignancies: Clinico-pathological correlations and prognostic implications.

Affiliation: Aarhus University Hospital, Dept. of Hematology

Phd. Student: Maja Ølholm Vase

Period: 2012-2015

Status: ONGOING

B) Co-supervisor

1) Title: Retrovirally induced murine models of malignant lymphomas investigated by gene expression analysis and RNA interference technology

Affiliation: Aarhus University, Dept. of Molecular Biology

Phd student: Magdalena Pyrz, stud.scient.

Status: ACCOMPLISHED (Thesis: spring 2008)

2) Title: Studies of gene cooperativity in tumor development induced by replication competent retroviral vectors harbouring ras genes

Affiliation: Aarhus University, Dept. of Molecular Biology

Phd student: Borja Ballarin-Gonzalez, stud.scient.

Status: ACCOMPLISHED (Thesis: summer 2008)

3) Title: Protein profiling of lymphomas. Identification and characterization of disease markers and drug targets

Affiliation: Medical Biochemistry, Aarhus University

Phd student: Maja Ludvigsen, cand.scient.

Status: ACCOMPLISHED. (Thesis: Maj 2014)

4) Title: Cellulær immunitet samt udviklingen af sekundær cancer efter immunsuppression

Affiliation: Aarhus Universitetshospital, Dept. of Gynecology

Phd student: Line Vinther, cand. med.

Status: ONGOING

5) Title: Exposure to Styrene and risk of cancer (STRIKT- Project): A 40 year follow-up on workers in the Danish reinforced plastics industry

Affiliation: Aarhus University Hospital, Dept. of Occupational Medicine

Phd student: Mette Skovgaard Christensen, cand. med.

Status: ONGOING

I) RECENT GRANTS

1) Grant from : Nordisk Cancer Union

Project: Nordic Lymphoma Group - A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue (NLG-T-01)

Amount: 78.277 DKK (2006); 96.633 DKK (2007)

Grant start: 2006, 2007, 2008, 2009, 2010

Purpose: Economic support for clinical trial activities within the Nordic phase II study on peripheral T-cell lymphomas (NLG-T-01)

2)Grant from: Bayer-Schering Pharma

Project: Nordic Lymphoma Group - A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone in young and elderly patients with previously untreated systemic peripheral T-cell lymphomas

Amount: 4.309.601 DKK

Grant start: 2006

Purpose: Economic support for clinical trial activities within the international multicenter phase III study on peripheral T-cell lymphomas (ACT-1 trial)

3)Grant from: Eva & Henry Frænkels Mindefond (Phd student, M.D. Esben Søndergaard)

Project: A Single-centre Experience of Clinico-Pathological Features, Risk Factors and Treatment Outcome of Posttransplant Lymphoproliferative Disorders after Renal Transplantation

Amount: 100.000 DKK

Grant start: 2008

Purpose: A clinical and molecular study of PTLD cases in renal transplant patients diagnosed and treated at Aarhus University Hospital during the period 1990-2005

4)Grant fromGrosserer M. Brogaard og Hustrus Mindefond (Phd student, M.D. Esben Søndergaard)

Project: A Single-centre Experience of Clinico-Pathological Features, Risk Factors and Treatment Outcome of Posttransplant Lymphoproliferative Disorders after Renal Transplantation

Amount: 40.000 DKK

Grant start: 2008

Purpose: A clinical and molecular study of PTLD cases in renal transplant patients diagnosed and treated at Aarhus University Hospital during the period 1990-2005

5)Grant from: Karen Elise Jensens Foundation

Project: Klinisk Forskning i Maligne Lymfoproliferative Sygdomme

Amount: 1.927.500 DKK

Grant start: 2010

Purpose: Consolidate and expand a multidisciplinary consortium on the identification of potential therapeutic molecular targets and implementation of targeted therapies in malignant lymphoproliferative diseases – Grant specifically intended to support the establishment of a project-dedicated clinical research professorship

6)Grant from: Research Funds – Cancer Center at Aarhus University Hospital

Projekt: Clinical Research in Malignant Lymfoproliferative Diseases

Amount: 300.000 DKK

Grant Start: 2010

J) OPPONENT AT SCIENTIFIC DISSERTATIONS AND SIMILAR ACTIVITIES

1) Role: Member of Evaluation Committee

Type of dissertation: Dr.med.sc. degree

Title: Mantle cell lymphoma: molecular, biological and clinical findings

Candidate: Dr. Niels Smedegaard Andersen, Dept. of Hematology, Rigshospitalet, Copenhagen

Dissertation date: 16.6.2005

Institution: University of Copenhagen

2) Role: Chairman Poster Session, Ph.D day 2008, Aarhus University

3) Role: Member of Evaluation Committee

Type of Dissertation: Ph.D Degree

Title: The Biological and prognostic significance of non-neoplastic bystander cells in Hodgkin lymphoma

Candidate: Peter Kamper, M.D. Dept. of Hematology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark

Dissertation date: 04.02.2011

Institution: University of Aarhus

4) Role: Member of Evaluation Committee

Type of Dissertation: Ph.D. degree

Title: Inflammatory cells and prognosis in primary melanoma

Candidate: Trine Øllegaard M.D. Dept. of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Aarhus, Denmark

Dissertation date: 25.02.2011

Institution: University of Aarhus

5) Role: Member of Copenhagen University Assessment Committee

Type of assessment: Professorship in Malignant lymphoproliferative diseases at Copenhagen University

Title: Malignant Lymphoproliferative Diseases

Institute: Department of Surgery and Internal Medicine, University of Copenhagen

Date: March 2011

6) Role: Member of Evaluation Committee

Type of Dissertation: Ph.D. degree.

Title: Prognostic characteristics of diffuse large B-cell lymphoma.

Candidate: Gustaf Hedström, M.D., Dept. of Oncology, Uppsala University Hospital, Sweden.

Dissertation date: 26.04.14

Institution: Uppsala University Hospital, Sweden.

K) ROLE IN ONGOING INTERNATIONAL CLINICAL TRIALS.

International Principal Investigator:

1.: A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas (ACT-1).

Funktion: Overall principal investigator (PI)

National Principal Investigator:

2.: A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma DSHNHL 2006-1B. (ACT-2).

Funktion : National PI

3.: Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance

in patients with diffuse large B-cell lymphoma (HOVON 84).

Funktion: National PI

4.: An open-label, multi-centre, dose escalating, phase I/randomized phase II

study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease (GAUSS).

Funktion: National PI

5.: A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL).

Funktion: National PI

6.: Et prospektivt, fase II multicenterforsøg med MabThera® (rituximab) plus CHOP hver anden uge efterfulgt af lavdosis helkropsbestråling hos ældre patienter med diffust storcellet B-celle-lymfom (LDTBI)

Funktion: Overall PI

7.: Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL (ORCHARRD).

Funktion: National PI

8.: Randomised Study Comparing 4 and 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, both with Cycles of Immunotherapy with the Monoclonal anti-CD20 Antibody Rituximab in Patients with Aggressive CD20-positive B-Cell Lymphoma Aged 18 to 60 Years with no Risk Faktor (Age-adjusted IPI=0) and no Bulky Disease (Diameter <7,5cm)(FLYER)

Funktion: Centre PI

9.: A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy (PRIMA).

Funktion: Centre PI

10.: A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose

consolidation with autologous stem cell rescue (NLG-T-01).

Funktion: Overall PI

L) GCP-RELATED ACTIVITIES

- Internal Review Board (IRB) certification test, University of Nebraska Medical Center, Omaha, Nebraska, USA, July 2005.

- Teaching Faculty, National GCP Course for monitors, research nurses and clinical trial officers, GCP Unit, Aarhus University, April 2009

- Investigator initiated trials and Good Clinical Practice, Chairman and speaker, Bispebjerg Hospital, January 2013.

EFGCP Workshop on "Striving for Professionalism in IITs", February, Brussels, Belgium.

Investigator initiated trials and Good Clinical Practice, Chairman and speaker, Bispebjerg Hospital, April 2014.

M) ADMINISTRATIVE POSITIONS

One of the three administrative heads (funktionsleder) of the Lymphoma Unit, Dept. of Hematology, Aarhus University Hospital

N) OTHER PRESENT POSITIONS

Chairman of the Working Group on T-cell lymphomas of the Nordic Lymphoma Group

Member of the Board of the Danish Cutaneous Lymphoma Group

O) REVIEWER AND EDITORIAL BOARD ACTIVITIES

Abstract reviewer for EHA 2018, Topic: Aggressive Lymphomas.
UK Cancer Research – Grant application reviewer

External reviewer for the Swedish Research Council for the evaluation of the Scientific Quality of Clinical research in Sweden for the period 2012-2015.

External application reviewer for professorship in 'Targeted Therapy' at Manchester University

Leukemia and Lymphoma

European Journal of Hematology

Radiotherapy and Oncology

Blood, The Journal of the American Association of Hematology

Reviewer of Ph.D project proposals, Aarhus University

Haematologica

Annals of Oncology

Abstract Reviewer for the European Haematology Association

P) EXPERT ADVISE FOR GOVERNMENTAL AND INTERGOVERNMENTAL AGENCIES.

Member of an expert counselling panel for the elaboration of a national diagnostic algorithm for malignant lymphoma – National Board of Health, Denmark.

Member of an expert counselling panel for the registration of new drugs in peripheral T-cell lymphomas – European Medicine Agency, London, UK.

Member of the Clinical Advisory Committee of the 2017 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.

Coordinating Author to the ESMO Clinical Practice Guidelines on T-cell Lymphomas.

Q) COLLABORATIVE PROJECTS.

1)Topic: Internationalt fase III studie om alemtuzumab i den primærebehandling af perifere T-celle lymfomer (PTCL) (ACT-1 og ACT-2 protokoller).

Partner: Professor Lorenz Trümper og professor Gerald Wulf.

Institution: Dept. of Hematology and Oncology, University Hospital Göttingen.

2)Topic:Nordisk fase II studie om autolog stamcelletransplantation i den primære behandling af PTCL (NLG-T-01).

Partner: Danske, norske, svenske og finske centre fra Nordisk Lymfomgruppe.

Institution: Universitetshospitaler i Norden

3)Topic: Genexpressionsprofil af PTCL undertyper

Partner: Professor W.W. Chan

Institution: Dept. of Pathology, University of Nebraska Medical Centre, Omaha, Nebraska

4)Topic: Whole exomic sequencing og T/NK cell derived lymphoid malignancies from Asian and Caucasian patients.

Partner: Prof. Wang Seog Kim

Institution: Samsung University Center, Seoul, South Korea

5)Topic: Undersøgelser af gammadelta T-celler hos patienter med Crohn's sygdom behandlet med anti-TNF-alfa præparater.

Partner: Ovl., Ph.D, Jens Kelsen, Ovl., dr. med. Jens Dahlerup og Ph.D. stud., læge, Anders K. Dige

Institution: Gastroenterologisk afdeling V, Århus Universitetshospital, AS-NBG

6)Topic: Proteomics analyser af maligne lymfomer.

Partner: Professor Bent Honoré og Ph.D. Maja Ludvigsen

Institution: Institut for Medicinsk Biokemi, Århus Universitet

7)Topic: Histopatologisk undersøgelse af maligne lymfomer

Partner: Professor Stephen Hamilton-Dutoit, overlæge, dr. med. Knud Bendix.

Institution: Patologisk Institut, Århus Universitetshospital, AS-NBG og THG.

8)Topic: Lavdosis helkropsbestråling af maligne lymfomer

Partner: Overlæge Akmal Safwat, professor Jens Overgaard

Institution: Afd. for Eksperimentel Onkologi, ÅUH, AS-NBG

9) Topic: PET ved maligne lymfomer

Partner: Overlæge Lars Gormsen

Institution: Nuklearmedicinsk afdeling, AUH, AS-NBG

10) Topic: Post-transplantation lymfoproliferative sygdomme

Partner: Professor, ovl. dr. med. Bente Jespersen

Institution: Nefrologisk afdeling C, AUH, Skejby

11) Topic: Epigenetiske og funktionelle studier af maligne lymfomer

Partner: Lektor, dr. med. Steffen Junker

Institution: Inst. for Human Genetik, Århus Universitet

12) Topic: Stereologiske studier af immunhistokemiske farvninger ved maligne lymfomer.

Partner: Professor Jens Nyengaard

Institution: Stereologisk Forskningslaboratorium, Patologisk Institut, AUH, AS-NBG

13) Topic: HPV-associeret cervix dysplasi/cancer hos immun supprimerede hæmatologiske patienter.

Partner: (i) Professor Jan Blaakjær, (ii) Professor Henrik Toft Soerensen

Institution: (i) Gynækologisk afdeling Y, AUH, Skejby, (ii) Klinisk Epidemiologisk...etc.

14) Topic: Risiko for udvikling af ALCL hos patienter med brystimplantat

Partner: Professor Henrik Toft Sørensen

Institution: Klinisk Epidemiologisk afdeling, Klinisk Institut, Århus Universitet.

15) Topic: Forekomst af maligne lymfomer hos minkavlere

Partner: Professor Henrik Toft Sørensen

Institution: Klinisk Epidemiologisk afdeling, Klinisk Institut, Århus Universitet

16) Topic: Bioinformatics

Partner: Professor Mikkel Heide Schiebe

Institution: Bioinformatic Research Center (BIRC), Aarhus University, Aarhus, Denmark

17) Topic: Whole exomic sequencing in familial Hodgkin Lymphoma

Partner: Professor Lauri Aaltonen

Institution: Institute of Human Genetics, Helsinki Biomedicum, Helsinki University, Helsinki, Finland.

R) INVITED SPEAKER/CHAIRMAN 2009-2014 (INTERNATIONAL MEETINGS ONLY)

1. Status: Invited speaker

Meeting title: International T-cell Lymphoma Forum

Meeting site and date: San Francisco, USA – January 2012

Organizer: International T-cell Lymphoma Forum - Scientific Committee

Title of talk: Improving treatment strategies in PTCL - The Nordic Lymphoma Group experience

2. Status: Invited speaker

Meeting title :Annual Cancer Symposium

Meeting site and date: Helsinki, Finland - February 2012

Organizer: Finnish Cancer Foundation

Title of talk: Recent advances in the treatment of peripheral T-cell lymphomas

3. Status: Invited speaker

Meeting title: T-cell Lymphomas: Work in Progress 2009....2012

Meeting site and date: Bologna, Italy - September 2012

Organizer: T-cell lymphomas: Work in progress - Scientific Committee

Title of talk: High dose Therapy in PTCL

4. Status: Invited speaker

Meeting title: FHL-meeting

Meeting site and date: Tallin, Estonia - October 2012

Organizer: Nordic Lymphoma Group

Title of talk: Introduction of the HL family.

5. Status: Invited speaker

Meeting title: Modern Approaches to the lymphoma diagnostics and treatment

Meeting site and date: Kyiv, Ukraine - October 2012

Organizer: Hematology.org.

Title of talk: Treatment of newly diagnosed and relapsed/refractory PTCL

6. Status:Invited speaker

Meeting title: XVI meeting of the European Association of Hematopathology

Meeting Site and date: Lisbon, Portugal - October 2012

Organizer: EAHP - European Association of Hematopathology -Scientific Committee

Title of talk: Recent Therapeutic advances in peripheral T-cell lymphomas.

7. Status: Invited speaker

Meeting title: International T-cell Forum.

Meeting site and date: San Francisco, USA - January 2013

Organizer: International T-cell Forum - Scientific Committee

Title of talk: Should ASCT in 1st remission be the standard of care for patients with PTCL

8. Status: Invited speaker

Meeting title: The 18th Congress of EHA

Meeting site and date: Stockholm, Sweden - June 2013

Organizer: EHA - Scientific Committee

Title of talk:Non-Hodgkin Lymphoma

9. Status: Invited speaker

Meeting title: Pfizer Satellite Symposium

Meeting site and date: 12th International Conference on Malignant Lymphoma, ICML, LuganoSwitzerland - June 2013

Organizer: Pfizer Oncology

Title of talk: PTCL: An elderly patient with advanced disease

10. Status: Invited speaker

Meeting title: 11th International Workshop on Non-Hodgkin Lymphoma

Meeting site and date: Dublin, Ireland -September 2013

Organizer: iwNHL - Scientific Committee

Title of talk: What has to change to make meaningful improvements in ALCL og AITL?

11. Status: Invited speaker

Meeting title: Post-ICML Meeting

Meeting site and date :Seoul, Korea October 2013

Organizer: Post-ICML - Scientific Committee

Title of talk: Peripheral T-cell lymphomas: Highlights from ICML-12

12. Status: Invited speaker

Meeting title: The 2nd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies

Meeting site and date: Berlin, Germany - October 2013

Organizer: COSTEM - Scientific Committee

Title of talk: Should peripheral T-cell Lymphoma be treated by auto or allogenic SCT?

13. Status: Invited speaker

Meeting title: International T-cell Forum

Meeting site and date: San Francisco, USA - January 2014

Organizer: International T-cell LYmphoma Forum - Scientific Committee

Title of talk: Making the case for allogeneic stem cell transplant before autologous: Is it ever appropriate?

14. Status: Invited speaker

Meeting title: The 19th Congress of the EHA

Meeting site and date: Milan, Italy - June 2014

Organizer: EHA - Scientific Committee

Title of talk: Challenging CD30+ lymphomas

15. Status: Invited speaker

Meeting title: DGHO-symposium

Meeting site and date: Hamburg, Germany - October 2014

Organizer: DGHO - Scientific Committee

Title of talk: Clinical experience with Pixantrone

16. Status: Invited speaker

Meeting title: Istanbul EMBT

Meeting site and date: Istanbul, Turkey - March 2015

Organizer: Istanbul EMBT - Scientific Committee

Title of talk: Peripheral T-cell Lymphomas

17. Status: Invited speaker

Meeting title: Takeda Satellite Symposium

Meeting site and date: EHA 2015, 20th Congress of European Hematology Association, Vienna - June 2015

Organizer: Takeda

Title of talk: The evolving role on CD30 in B- and T-cell Lymphomas

18. Status: Invited speaker

Meeting title: CTI Satellite Symposium

Meeting site and date: 13th International Conference on Malignant Lymphoma, ICML.

Lugano, Switzerland - June 2015

Organizer: CTI - Scientific Committee

Title of talk: The Nordic PRE-Ben/PE-Ben experience

19. Status: Invited speaker

Meeting title: 15th Lymphoma Summit

Meeting site and date: Tokyo, Japan - September 2015

Organizer: 15th Lymphoma Summit - Scientific Committee

Title of talk: Current Clinical Trials of Nordic Lymphoma Study Group in PTCL

20. Status: Invited speaker

Meeting title: Swedish Lymphoma Group Meeting

Meeting site and date: Stockholm, Sweden - September 2015

Organizer: Swedish Lymphoma Group - Scientific Committee

Title of talk: Primary Systemic Peripheral T-cell Lymphomas

21. Status: Invited speaker

Meeting title: New Perspectives and Future Clinical Development in Hematooncology

Meeting site and date: Amsterdam, The Netherlands - September 2015

Organizer: Servier

Title of talk: Novel regimens in late stage refractory high grade NHL - The Nordic Experience

22. Status: Invited speaker

Meeting title: ECCO-Congress

Meeting site and date: Vienna, Austria - September 2015

Organizer: ECCO - Scientific Committee

Title of talk: Frontline Treatment

23. Status: Invited speaker

Meeting title: iwNHL Meeting

Meeting site and date: Baveno, Italy - October 2015

Organizer: iwNHL -Scientific Committee

Title of Talk: Improving Treatment Strategies in PTCL

24. Status: Invited speaker

Meeting title: Lecture on Pixuvri - Symposium Spanish Society of Hematology

Meeting site and date: Valencia, Spain - October 2015

Organizer: SSH - Scientific Committee

Title of talk: PTCL: European experience with Pixantrone

25. Status: Invited speaker

Meeting title: Lymphoma Forum of Ireland

Meeting site and date: Co Kildare, Ireland - November 2015

Organizer: Lymphoma Forum Ireland - Scientific Committee

Title of talk: How do we manage T-NHL in 2015

26. Status: Invited speaker

Meeting title: International T-cell Forum

Meeting site and date: San Francisco, USA - January 2016

Organizer: International T-cell Forum - Scientific Committee

Title of talk: Can we define the optimal patient populations for auto or allo transplant in PTCL?

27. Status: Invited speaker

Meeting title: 2nd postgraduate Lymphoma Conference.

Meeting site and date: Rome, Italy - March 2016

Organizer: 2nd postgraduate Lymphoma Conference - Scientific Committee

Title of talk: Should ASCT in 1st Remission be the standard of care for patients with PTCL?

28. Status: Invited speaker

Meeting title: Clinical Challenge in the management of relapsed/refractory Aggressive B-cell NHL: Role of Salvage Options and new Perspectives.

Meeting site and date: Valencia, Spain - April 2016

Organizer: CTI/Servier - Scientific Committee

Title of talk: Alternate Regimens in late stage, refractory High-grade NHL: new data from the PREBEN case series

29. Status: Invited speaker

Meeting title: VIII International Florence Meeting on Hematology

Meeting Site and date: Florence, Italy - April 2016

Organizer: VIII International Florence Meeting on Hematology - Scientific Committee

Title of talk: Innovative Aspects.

30. Status: Invited Speaker

Meeting title: Master Class Finnish Lymphoma Group

Meeting Site and date: Helsinki, Finland - April 2016

Organizer: Master Class Finnish Lymphoma Group - Scientific Committee.

Title of talk: T-cell Lymphoma overview

31. Status: Invited speaker

Meeting Title: Blutiger Donnerstag

Meeting site and date: Vienna, Austria - April 2016

Organizer: Philipp Staber - General Hospital Vienna

Title of talk: The upfront management of patients with systemic PTCL: Considerations on the role of SCT and the choice of chemotherapy backbone

32. Status: Invited speaker

Meeting title: Memorial Sloan Kettering Symposium on Lymphoma

Meeting site and date: New York, USA - May 2016

Organizer: MSKSL - Scientific Committee

Title of talk: T-cell lymphoma overview

33. Status: Invited speaker

Meeting title: 1st. Nordic Meeting on Tumor Microenvironment in Lymphoma

Meeting site and date: Aarhus, Denmark - May 2016

Organizer: 1st. Nordic Meeting on Tumor Microenvironment in Lymphoma - Scientific Committee.

Title of talk: Selected Nordic Data in PTCL

34. Status: Invited speaker

Meeting title: Servier symposium "optimizing salvage therapy in relapsed aggressive NHL"

Meeting site and date: Copenhagen, Denmark - June 2016

Organizer: Servier

Title of talk: Novel combination regimen: New results in relapsed/refractory aggressive NHL

35. Status: Invited speaker

Meeting title: European Concepts in Malignant Lymphoma

Meeting site and date: Heidelbergm Germany - September 2016

Organizer: Heidelberg University

Title of talk: How I treat T-cell Lymphomas

36. Status: Invited speaker

Meeting title: European School of Hematology

Meeting site and date: Paris, France - February 2017

Organizer: European School of Hematology - Scientific Committee

Title of talk: Case based Lecture. Young Patients, First Line.

37. Status: Invited speaker

Meeting title: EHA SWG on Rare Lymphomas

Meeting site and date: Barcelona, Spain - March 2017

Organizer: EHA SWG - Scientific Committee

Title of talk: Novel Treatment Options.

38. Status: Invited speaker

Meeting title: 2nd Nordic Meeting on Tumor Microenvironment in Lymphoma

Meeting site and date: Aarhus, Denmark - May 2017

Organizer: 2nd Nordic Meeting on Tumor Microenvironment in Lymphoma - Scientific Committee

Title of talk: NLG-T-01/ACT

39. Status: Invited speaker

Meeting title: Korean Society of Hematology Annual Meeting

Meeting site and date: Seoul, Korea - May 2017

Organizer: Korean Society of Hematology - Scientific Committee

Title of talk: Role of Transplantation in PTCL

40. Status: Invited speaker

Meeting title: Czech Hematology Annual Meeting

Meeting site and date: Olomouc, Czech - May 2017

Organizer: Czech Hematology - Scientific Committee

Title of talk: Aggressive Non-Hodgkin Lymphoma in the elderly

41. Status: Invited speaker

Meeting title: 14th International Conference on Malignant Lymphoma, ICML

Meeting site and date: Lugano, Switzerland - June 2017

Organizer: ICML - Scientific Committee

Title of talk: Meet the Professor Lecture: ALCL and PTCL: What a pediatric and adult oncologist can learn from each other?

42:Status: Invited speaker

Meeting title: 15th iwNHL Meeting

Meeting site and date: Vancouver, Canada - September 2017

Organizer: iwNHL -Scientific Committee

Title of talk: Latest advances in treatment of T-cell lymphomas